Literature DB >> 28197530

Mutant p53-Nrf2 axis regulates the proteasome machinery in cancer.

Kamil Lisek1, Dawid Walerych1, Giannino Del Sal2.   

Abstract

The proteasome machinery is a common target of gain-of-function p53 missense mutants. Upregulation of the proteasome fosters chemoresistance to proteasome inhibitors. In triple negative breast cancer cells this resistance mechanism, namely the Nrf2-regulated "bounce-back" response to proteasome inhibitors, can be overcome by targeting p53 mutant proteins with APR-246/PRIMA-1Met.

Entities:  

Keywords:  APR-246; Chip-seq; Keap1; Nrf2; TNBC; cancer; multi-omics; mutant p53; proteasome; proteomics; transcriptomics

Year:  2016        PMID： 28197530      PMCID： PMC5286961          DOI： 10.1080/23723556.2016.1217967

Source DB:  PubMed          Journal:  Mol Cell Oncol        ISSN： 2372-3556


  10 in total

1.  Mutant p53R273H attenuates the expression of phase 2 detoxifying enzymes and promotes the survival of cells with high levels of reactive oxygen species.

Authors:  Eyal Kalo; Ira Kogan-Sakin; Hilla Solomon; Elad Bar-Nathan; Moshe Shay; Yoav Shetzer; Elya Dekel; Naomi Goldfinger; Yossi Buganim; Perry Stambolsky; Ido Goldstein; Shalom Madar; Varda Rotter
Journal:  J Cell Sci       Date:  2012-08-16       Impact factor: 5.285

Review 2.  Modulation of oxidative stress as an anticancer strategy.

Authors:  Chiara Gorrini; Isaac S Harris; Tak W Mak
Journal:  Nat Rev Drug Discov       Date:  2013-12       Impact factor: 84.694

Review 3.  Targeting triple negative breast cancer: is p53 the answer?

Authors:  Natalie Turner; Erica Moretti; Olimpia Siclari; Ilenia Migliaccio; Libero Santarpia; Maurizio D'Incalci; Stefano Piccolo; Andrea Veronesi; Alberto Zambelli; Gianni Del Sal; Angelo Di Leo
Journal:  Cancer Treat Rev       Date:  2013-01-12       Impact factor: 12.111

4.  Proteasome machinery is instrumental in a common gain-of-function program of the p53 missense mutants in cancer.

Authors:  Dawid Walerych; Kamil Lisek; Roberta Sommaggio; Silvano Piazza; Yari Ciani; Emiliano Dalla; Katarzyna Rajkowska; Katarzyna Gaweda-Walerych; Eleonora Ingallina; Claudia Tonelli; Marco J Morelli; Angela Amato; Vincenzo Eterno; Alberto Zambelli; Antonio Rosato; Bruno Amati; Jacek R Wiśniewski; Giannino Del Sal
Journal:  Nat Cell Biol       Date:  2016-06-27       Impact factor: 28.824

5.  Mutant p53 inhibits miRNA biogenesis by interfering with the microprocessor complex.

Authors:  F Garibaldi; E Falcone; D Trisciuoglio; T Colombo; K Lisek; D Walerych; G Del Sal; P Paci; G Bossi; G Piaggio; A Gurtner
Journal:  Oncogene       Date:  2016-03-21       Impact factor: 9.867

Review 6.  The Dual Roles of NRF2 in Cancer.

Authors:  Silvia Menegon; Amedeo Columbano; Silvia Giordano
Journal:  Trends Mol Med       Date:  2016-06-02       Impact factor: 11.951

7.  Oncogene-induced Nrf2 transcription promotes ROS detoxification and tumorigenesis.

Authors:  Gina M DeNicola; Florian A Karreth; Timothy J Humpton; Aarthi Gopinathan; Cong Wei; Kristopher Frese; Dipti Mangal; Kenneth H Yu; Charles J Yeo; Eric S Calhoun; Francesca Scrimieri; Jordan M Winter; Ralph H Hruban; Christine Iacobuzio-Donahue; Scott E Kern; Ian A Blair; David A Tuveson
Journal:  Nature       Date:  2011-07-06       Impact factor: 49.962

Review 8.  Targeting of Mutant p53 and the Cellular Redox Balance by APR-246 as a Strategy for Efficient Cancer Therapy.

Authors:  Vladimir J N Bykov; Qiang Zhang; Meiqiongzi Zhang; Sophia Ceder; Lars Abrahmsen; Klas G Wiman
Journal:  Front Oncol       Date:  2016-02-03       Impact factor: 6.244

Review 9.  Mutant p53: One, No One, and One Hundred Thousand.

Authors:  Dawid Walerych; Kamil Lisek; Giannino Del Sal
Journal:  Front Oncol       Date:  2015-12-21       Impact factor: 6.244

Review 10.  The Nrf2 regulatory network provides an interface between redox and intermediary metabolism.

Authors:  John D Hayes; Albena T Dinkova-Kostova
Journal:  Trends Biochem Sci       Date:  2014-03-16       Impact factor: 13.807
  10 in total
  7 in total

Review 1.  NRF2 and the Hallmarks of Cancer.

Authors:  Montserrat Rojo de la Vega; Eli Chapman; Donna D Zhang
Journal:  Cancer Cell       Date:  2018-05-03       Impact factor: 31.743

2.  Kelch-like ECH-associated protein 1 (KEAP1) differentially regulates nuclear factor erythroid-2-related factors 1 and 2 (NRF1 and NRF2).

Authors:  Wang Tian; Montserrat Rojo de la Vega; Cody J Schmidlin; Aikseng Ooi; Donna D Zhang
Journal:  J Biol Chem       Date:  2017-12-18       Impact factor: 5.157

3.  Small-Molecule NSC59984 Induces Mutant p53 Degradation through a ROS-ERK2-MDM2 Axis in Cancer Cells.

Authors:  Shengliang Zhang; Lanlan Zhou; Wafik S El-Deiry
Journal:  Mol Cancer Res       Date:  2022-04-01       Impact factor: 5.852

4.  Lithocholic Acid, a Metabolite of the Microbiome, Increases Oxidative Stress in Breast Cancer.

Authors:  Patrik Kovács; Tamás Csonka; Tünde Kovács; Zsanett Sári; Gyula Ujlaki; Adrien Sipos; Zsolt Karányi; Dóra Szeőcs; Csaba Hegedűs; Karen Uray; Laura Jankó; Máté Kiss; Borbála Kiss; Damya Laoui; László Virág; Gábor Méhes; Péter Bai; Edit Mikó
Journal:  Cancers (Basel)       Date:  2019-08-27       Impact factor: 6.639

5.  Therapeutic targeting of mutant p53 in pediatric acute lymphoblastic leukemia.

Authors:  Salih Demir; Elena Boldrin; Qian Sun; Stephanie Hampp; Eugen Tausch; Cornelia Eckert; Martin Ebinger; Rupert Handgretinger; Geertruy Te Kronnie; Lisa Wiesmüller; Stephan Stilgenbauer; Galina Selivanova; Klaus-Michael Debatin; Lüder Hinrich Meyer
Journal:  Haematologica       Date:  2019-05-09       Impact factor: 9.941

Review 6.  The Anticancer Effects of Flavonoids through miRNAs Modulations in Triple-Negative Breast Cancer.

Authors:  Getinet M Adinew; Equar Taka; Patricia Mendonca; Samia S Messeha; Karam F A Soliman
Journal:  Nutrients       Date:  2021-04-07       Impact factor: 5.717

7.  Harnessing the vulnerabilities of p53 mutants in lung cancer - Focusing on the proteasome: a new trick for an old foe?

Authors:  Eziafa I Oduah; Steven R Grossman
Journal:  Cancer Biol Ther       Date:  2020-02-10       Impact factor: 4.742
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.